Home Medicine Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice
Article
Licensed
Unlicensed Requires Authentication

Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice

  • Laurent Ramont , Henri Thoannes , Ariel Volondat , François Chastang , Marie-Christine Millet and François-Xavier Maquart
Published/Copyright: October 19, 2005
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 43 Issue 11

Abstract

The concentration of neuron-specific enolase (NSE) in serum and cerebrospinal fluid (CSF) has been used as a biomarker in some cancers and, more recently, in neurodegenerative diseases. Pre-analytical conditions are very important for the quality of returned results. In this study, we evaluated the effects of storage conditions (temperature and duration of storage) and hemolysis on the concentration of NSE in serum and CSF. Our results demonstrate that samples for NSE measurement may be stored at −80°C for no more than 6 months in the case of CSF and 9months in the case of serum samples. Even invisible hemolysis may increase NSE levels in samples. Consequently, an index of hemolysis should be determined before deciding whether or not to perform NSE measurement.

Keywords: cerebrospinal fluid; hemolysis; neuron-specific enolase; serum; storage conditions
Corresponding author: Dr. Laurent Ramont, MD, PhD, Laboratoire Central de Biochimie, Hôpital Robert Debré, Centre Hospitalier Universitaire, Avenue du Général Koenig, 51092 Reims Cedex, France Phone: +33-3-26783181, Fax: +33-3-26788539,

References

1. Cooper EH. Neuron-specific enolase. Int J Biol Markers 1994; 9:205–10.10.1177/172460089400900401Search in Google Scholar

2. Gerbitz KD, Summer J, Schumacher I, Arnold H, Kraft A, Mross K. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem 1986; 24:1009–16.10.1515/cclm.1986.24.12.1009Search in Google Scholar

3. Niklinski J, Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev 1995; 4:129–38.10.1097/00008469-199504000-00002Search in Google Scholar

4. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10:4–12.10.1158/1078-0432.CCR-1051-2Search in Google Scholar

5. Aksamit AJ, Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 2001; 57:728–30.10.1212/WNL.57.4.728Search in Google Scholar

6. Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in CSF for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003; 40:25–40.10.1258/000456303321016141Search in Google Scholar

7. Zuber E, Rosso L, Darbouret B, Socquet F, Mathis G, Flandrois JP. A descriptive model for the kinetics of a homogeneous fluorometric immunoassay. J Immunoassay 1997; 18:21–47.10.1080/01971529708005803Search in Google Scholar

8. Bissé E, Abraham EC. New less temperature-sensitive microchromatographic method for separation and quantitation of glycosylated hemoglobins using a non-cyanide buffer system. J Chromatogr 1985; 344:81–91.10.1016/S0378-4347(00)82009-5Search in Google Scholar

9. Beaudeux JL, Léger P, Dequen L, Gandjbakhch I, Coriat P, Foglietti MJ. Influence of hemolysis on the measurement of S-100β protein and neuron-specific enolase plasma concentrations during coronary artery bypass grafting. Clin Chem 2000; 46:989–90.10.1093/clinchem/46.7.989Search in Google Scholar

10. Mercer DW, Virji MA, Barry GE, Piper ML. New solid-phase enzyme immunoassay of neuron-specific enolase in serum: effect of storage temperature, lipemia, icterus, and hemolysis. Clin Chem 1990; 36:1519.10.1093/clinchem/36.8.1519Search in Google Scholar

Received: 2005-5-24
Accepted: 2005-8-3
Published Online: 2005-10-19
Published in Print: 2005-11-1

©2005 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region
  2. Isotretinoin therapy induces DNA oxidative damage
  3. Structural evaluation of plasma α2-macroglobulin in acute pancreatitis
  4. Failure of the PAXgene™ Blood RNA System to maintain mRNA stability in whole blood
  5. Reticulocyte hemoglobin measurement – comparison of two methods in the diagnosis of iron-restricted erythropoiesis
  6. Physical analysis of ejaculate to evaluate the secretory activity of the seminal vesicles and prostate
  7. Specificity of the 3H-triolein assay for pancreatic lipase in blood plasma
  8. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice
  9. Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men
  10. Prevalence of abnormal thyroid stimulating hormone and thyroid peroxidase antibody-positive results in a population of pregnant women in the Samara region of the Russian Federation
  11. Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum
  12. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis
  13. Mean and variance quality control for multiple correlated levels of replicated control samples
  14. Clinical evaluation of serodiagnosis of active tuberculosis by multiple-antigen ELISA using lipids from Mycobacterium bovis BCG Tokyo 172
  15. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010
  16. Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult
  17. Deficient α-galactosidase A activity in plasma but no Fabry disease – a pitfall in diagnosis
  18. Reportable interval of patient examination results and ISO 15189
https://doi.org/10.1515/CCLM.2005.210
Keywords for this article
cerebrospinal fluid; hemolysis; neuron-specific enolase; serum; storage conditions

Articles in the same Issue

  1. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region
  2. Isotretinoin therapy induces DNA oxidative damage
  3. Structural evaluation of plasma α2-macroglobulin in acute pancreatitis
  4. Failure of the PAXgene™ Blood RNA System to maintain mRNA stability in whole blood
  5. Reticulocyte hemoglobin measurement – comparison of two methods in the diagnosis of iron-restricted erythropoiesis
  6. Physical analysis of ejaculate to evaluate the secretory activity of the seminal vesicles and prostate
  7. Specificity of the 3H-triolein assay for pancreatic lipase in blood plasma
  8. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice
  9. Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men
  10. Prevalence of abnormal thyroid stimulating hormone and thyroid peroxidase antibody-positive results in a population of pregnant women in the Samara region of the Russian Federation
  11. Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum
  12. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis
  13. Mean and variance quality control for multiple correlated levels of replicated control samples
  14. Clinical evaluation of serodiagnosis of active tuberculosis by multiple-antigen ELISA using lipids from Mycobacterium bovis BCG Tokyo 172
  15. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010
  16. Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult
  17. Deficient α-galactosidase A activity in plasma but no Fabry disease – a pitfall in diagnosis
  18. Reportable interval of patient examination results and ISO 15189
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 7.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2005.210/html
Scroll to top button